台湾食品和药物管理局正在审查珠穆朗玛峰药物“VELSIPITY”药物,以治疗严重的溃烂性结肠炎。 Everest Medicines' VELSIPITY® drug is under review by Taiwan's FDA for treating severe ulcerative colitis.

埃弗雷斯特药品公司的药物VELSIPITY® (etrasimod) 已被台湾FDA接受审查,用于治疗中度至重度的性结肠炎 (UC). Everest Medicines' drug VELSIPITY® (etrasimod) has been accepted for review by Taiwan's FDA for treating moderate to severe ulcerative colitis (UC). 该药物已经在若干亚洲市场得到批准,并在最新的ACG关于诱导和保持UC病人的戒毒治疗准则中被推荐。 The drug has already been approved in several Asian markets and is recommended in the latest ACG guidelines for inducing and maintaining remission in UC patients. 临床试验显示,VELSIPITY达到所有关键功效端点,具有有利的安全性特征。 Clinical trials showed VELSIPITY® met all key efficacy endpoints with a favorable safety profile.